Announcements Trials

Browse Landscape

Phase

Phase 2 136 Phase 3 32 Phase 1 19 Phase 1/2 13 Phase 4 5 Phase NA 4 Phase EARLY_PHASE1 4 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 21 Thoracic 7 Gynecologic 4 CNS 3 Other solid neoplasm 1 NET 1 Head & Neck 1 Endocrine 1 Breast 1

Conditions

Inflammatory Breast Neoplasms 1 Carcinoma, Ductal, Breast 1

Interventions

Capecitabine 17 Paclitaxel 16 Docetaxel 13 Carboplatin 12 Cyclophosphamide 11 Gemcitabine 9 Epirubicin 9 Trastuzumab 8 Letrozole 8 Doxorubicin 7 pertuzumab 5 Cisplatin 5 Vinorelbine 4 130-nm albumin-bound paclitaxel 4 exemestane 3 Zoledronic Acid 3 Tamoxifen 3 Neoadjuvant Therapy 3 Lapatinib 3 Injections 3 Drug Therapy 3 Ado-Trastuzumab Emtansine 3 AC protocol 3 pyrotinib 2 palbociclib 2 camrelizumab 2 apatinib 2 Thiotepa 2 Taxes 2 Standard of Care 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Bevacizumab × Breast × Clear all

NCT01426880 2016-02-15

GeparSixto

GBG Forschungs GmbH

Phase 2/3 Completed

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡